Related Experiment Video
Updated: Jun 8, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Update on chemotherapy for bladder cancer. Update 2010]
M M Heck1, J E Gschwend, M Retz
1Urologische Klinik und Poliklinik , Klinikum rechts der Isar, Technische Universität München, München.
Der Urologe. Ausg. A
|September 23, 2010
Summary
This review covers neoadjuvant and adjuvant trials for advanced bladder cancer and chemotherapy for metastatic urothelial cancer. Future treatments will increasingly use molecular profiling for personalized therapy.
Area of Science:
- Oncology
- Urothelial Carcinomas
- Cancer Therapy
Context:
- Locally advanced bladder cancer (LABC)
- Metastatic urothelial cancer (mUC)
- Systemic chemotherapy
- Neoadjuvant and adjuvant treatment strategies
Purpose:
- Review current evidence on neoadjuvant/adjuvant trials for LABC.
- Summarize data on systemic chemotherapy for mUC.
- Discuss emerging targeted therapies and molecular profiling in urothelial cancer.
Summary:
- Neoadjuvant and adjuvant chemotherapy trials show promise for LABC.
- Systemic chemotherapy remains a cornerstone for mUC.
- Targeted therapies and molecular profiling are gaining traction for personalized urothelial cancer treatment.
Impact:
- Informs clinical decision-making for advanced bladder cancer.
- Highlights the evolving landscape of urothelial cancer treatment.
- Emphasizes the future role of precision medicine in oncology.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:30Urinary Tract Calculi III: Medical Management
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...